Federal Register / Vol. 83, No. 150 / Friday, August 3, 2018 / Notices 38179 

210 of the Commission’s Rules of 

Practice and Procedure (19 CFR part 

210). 

By order of the Commission. 

Issued: July 30, 2018. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2018–16611 Filed 8–2–18; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: AMRI 

Rensselaer, Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before October 2, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: 

The Attorney General has delegated 

his authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on June 

25, 2018, AMRI Rensselaer, Inc., 33 

Riverside Avenue, Rensselaer, New 

York 12144 applied to be registered as 

a bulk manufacturer of the following 

basic classes of controlled substances: 

Controlled substance Drug code Schedule 

Marihuana ........................................................................................................................................................................ 7360 I 

Tetrahydrocannabinols .................................................................................................................................................... 7370 I 

Amphetamine ................................................................................................................................................................... 1100 II 

Lisdexamfetamine ............................................................................................................................................................ 1205 II 

Pentobarbital .................................................................................................................................................................... 2270 II 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................... 8333 II 

Codeine ........................................................................................................................................................................... 9050 II 

Oxycodone ....................................................................................................................................................................... 9143 II 

Hydromorphone ............................................................................................................................................................... 9150 II 

Hydrocodone ................................................................................................................................................................... 9193 II 

Meperidine ....................................................................................................................................................................... 9230 II 

Morphine .......................................................................................................................................................................... 9300 II 

The company plans to manufacture 

bulk controlled substances for use in 

product development and for 

distribution to its customers. 

In reference to drug codes 7360 

(marihuana) and 7370 (THC), the 

company plans to bulk manufacture 

these drugs as synthetics. No other 

activities for these drug codes are 

authorized for this registration. 

Dated: July 23, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–16635 Filed 8–2–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Notice of Lodging of Proposed 

Consent Decree Under the 

Comprehensive Environmental 

Response, Compensation and Liability 

Act 

On July 30, 2018, the Department of 

Justice lodged a proposed consent 

decree with the United States District 

Court for the Central District of 

California in the lawsuit entitled United 

States v. Honeywell International, Inc., 

Civil Action No. 2:18-cv-06556. 

The United States filed this lawsuit 

under the Comprehensive 

Environmental Response, 

Compensation, and Liability Act 

(CERCLA) for the recovery of costs that 

the United States incurred responding 

to releases of hazardous substances at 

Installation Restoration Program (IRP) 

Site 50 at Vandenberg Air Force Base in 

Santa Barbara County, California. The 

consent decree requires the defendant 

Honeywell International, Inc. to pay 

$250,000 to the United States. In return, 

the United States agrees not to sue the 

defendant under sections 106 and 107 of 

CERCLA at IRP Site 50 at Vandenberg 

Air Force Base. 

The publication of this notice opens 

a period for public comment on the 

proposed consent decree. Comments 

should be addressed to the Assistant 

Attorney General, Environment and 

Natural Resources Division, and should 

refer to United States v. Honeywell 

International, Inc., D.J. Ref. No. 90–11– 

3–10477/5. All comments must be 

submitted no later than thirty (30) days 

after the publication date of this notice. 

Comments may be submitted either by 

email or by mail: 

To submit 

comments: Send them to: 

By email ....... pubcomment-ees.enrd@

usdoj.gov. 

By mail ......... Assistant Attorney General, 

U.S. DOJ—ENRD, P.O. 

Box 7611, Washington, DC 

20044–7611. 

During the public comment period, 

the proposed consent decree may be 

examined and downloaded at this 

Justice Department website: https://

www.justice.gov/enrd/consent-decrees. 

We will provide a paper copy of the 

proposed consent decree upon written 

request and payment of reproduction 

costs. Please mail your request and 

payment to: Consent Decree Library, 

U.S. DOJ—ENRD, P.O. Box 7611, 

Washington, DC 20044–7611. 

Please enclose a check or money order 

for $5.25 (25 cents per page 


amozie on DSK3GDR082PROD with NOTICES1